These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26337642)

  • 1. [How to convince the head of department and managing director of the importance of specialised headache clinics].
    Riesco N; Garcia-Cabo C; Martinez-Ramos J; Pascual J
    Rev Neurol; 2015; 61 Suppl 1():S13-20. PubMed ID: 26337642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Creation and enhancement of headache units: the view of neurologists and heads of neurology departments].
    Leira R
    Rev Neurol; 2015; 61 Suppl 1():S9-S12. PubMed ID: 26337645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Organisation of headache units from a multidisciplinary point of view].
    Sanchez-Del-Rio Gonzalez M
    Rev Neurol; 2015; 61 Suppl 1():S21-6. PubMed ID: 26337643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Positioning of headache units in the field of neurology: the importance of OnabotulinumtoxinA and other therapies in the treatment of headaches].
    Torres-Ferrus M; Pozo-Rosich P
    Rev Neurol; 2015; 61 Suppl 1():S3-7. PubMed ID: 26337644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Specialised headache units, a feasible alternative in Spain].
    Pozo-Rosich P; Martin-Delgado J; Layos-Romero A; Pascual J; Bailón C; Guerrero-Peral AL; Ignacio E; Torres A; Mira JJ
    Rev Neurol; 2020 Sep; 71(6):199-204. PubMed ID: 32895902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adaptation of headache units in Andalusia to the COVID-19 pandemic. Analysis of the Andalusian Neurology Society's Headache Study Group].
    Lamas-Pérez R; Viguera-Romero FJ; Sánchez-Caballero F; Martínez-Simón J; Gómez-Camello A; González-Oria C
    Rev Neurol; 2022 Jan; 74(2):55-60. PubMed ID: 35014020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world economic impact of onabotulinumtoxinA in patients with chronic migraine.
    Rothrock JF; Bloudek LM; Houle TT; Andress-Rothrock D; Varon SF
    Headache; 2014; 54(10):1565-73. PubMed ID: 25298117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The impact of migraine and other primary headaches on the health system and in social and economic terms].
    Volcy-Gómez M
    Rev Neurol; 2006 Aug 16-31; 43(4):228-35. PubMed ID: 16883513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
    Mitchell MP; Schaecher K; Cannon HE; Speckman M
    J Manag Care Pharm; 2008 Jun; 14(5):442-50. PubMed ID: 18597573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention.
    Lipton RB; Silberstein SD
    Headache; 2015 Mar; 55 Suppl 2():103-22; quiz 123-6. PubMed ID: 25662743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Referrals from primary care to a dedicated headache clinic: analysis of the first 1,000 patients].
    Herrero-Velazquez S; Pedraza MI; Ruiz-Pinero M; Munoz I; Posadas J; de la Torre P; Bautista L; Guerrero-Peral AL
    Rev Neurol; 2014 Jun; 58(11):487-92. PubMed ID: 24861223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost effectiveness of Botox in Italian patients with chronic migraine.
    Ruggeri M
    Neurol Sci; 2014 May; 35 Suppl 1():45-7. PubMed ID: 24867835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Botulinum toxin injections for chronic migraine in adolescents - an early therapeutic option in the transition from neuropaediatrics to neurology].
    Bernhard MK; Bertsche A; Syrbe S; Weise S; Merkenschlager A
    Fortschr Neurol Psychiatr; 2014 Jan; 82(1):39-42. PubMed ID: 24446117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of chronic daily headache in migraine patients: medication overuse headache and chronic migraine. French guidelines (French Headache Society, French Private Neurologists Association, French Pain Society)].
    Lantéri-Minet M; Demarquay G; Alchaar H; Bonnin J; Cornet P; Douay X; Dousset V; Géraud G; Guillouf V; Navez M; Radat F; Radenne S; Revol A; Valade D; Donnet A
    Rev Neurol (Paris); 2014 Mar; 170(3):162-76. PubMed ID: 24594364
    [No Abstract]   [Full Text] [Related]  

  • 15. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK.
    Batty AJ; Hansen RN; Bloudek LM; Varon SF; Hayward EJ; Pennington BW; Lipton RB; Sullivan SD
    J Med Econ; 2013 Jul; 16(7):877-87. PubMed ID: 23647483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The epidemiology of headache and migraine, and its meaning for neurological services.
    Hopkins A
    Schweiz Med Wochenschr; 1996 Jan; 126(4):128-35. PubMed ID: 8578295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies.
    Smitherman TA; Burch R; Sheikh H; Loder E
    Headache; 2013 Mar; 53(3):427-36. PubMed ID: 23470015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The importance of headaches in neurology clinics. Study groups of neurologists of Aragon].
    Gracia-Naya M
    Rev Neurol; 1999 Sep 1-15; 29(5):393-6. PubMed ID: 10584239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Not Available].
    Sundal C; Tedroff J
    Lakartidningen; 2018 May; 115():. PubMed ID: 29762814
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of onabotulinumtoxinA for chronic migraine.
    Whitcup SM; Turkel CC; DeGryse RE; Brin MF
    Ann N Y Acad Sci; 2014 Nov; 1329():67-80. PubMed ID: 25399521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.